Our mission at D3 Bio is to build a global biotechnology company that develops innovative and more efficacious medicines for patients in need worldwide.

德昇济医药的使命是成为一家为患者开发更有效创新药的全球生物技术公司。

George Chen, MD

Co-Founder, Chairman & CEO

陈之键 博士

德昇济医药共同创始人、董事长兼首席执行官

About D3 Bio

D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated.  We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into lab to guide the identification of fit for purpose science and technology, and define our drug development path.  

D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Our portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio.  In fact, it underlies our name: Development leading to Discovery that then leads back to more Development, or D3 Bio.”

D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.

关于德昇济医药

德昇济医药是一家专注于肿瘤及免疫精准治疗药物开发的全球生物技术公司。德昇济医药现有的研发项目不仅旨在解决当前未满足的临床需求,也是赋能后续药物开发的核心“支柱”。目前新药管线拥有多个全球同类首个和/或同类最佳候选治疗药物。

德昇济医药通过内部研发和对外授权许可,综合地打造具有显著临床价值和协同效应的研发管线,更大限度地丰富和优化产品组合,开发更多的药物联用。这种持续推动药物发现和创新的循环开发正是德昇济医药的核心。公司的英文名D3Bio由此而来——开发(Development)→促进发现(Discovery),从而又带来更多开发(Development)。

德昇济医药的投资方由世界级的基金公司组成,包括博裕资本、经纬中国、红杉中国、淡马锡和药明康德风险投资基金。

Our vision

D3 Bio is to transform the lives of patients worldwide who suffer from the most difficult-to-treat, life threatening or debilitating conditions. Creating break-through precision medicines that match therapies to the disease biomarkers of individual patients, D3 Bio is committed to convert life-threatening cancers into manageable chronic conditions. We envision D3 Bio’s novel therapeutics would satisfy the unmet needs of cancer patients across the globe.

公司愿景

德昇济医药旨在开发革新性疗法,造福全球病患。

德昇济医药将早期新药发现与临床实践相结合,凭借源于临床开发的行业洞见,德昇济医药在肿瘤和免疫领域瞄准新的疾病靶点和递送途径,将严重威胁生命的癌症转化为可控制的慢性病,为患者提供更好的疗法,以解决未满足的全球临床需求。

Our team

D3 Bio brings a level of world-class experience at multinational big pharma companies that promises success for the Company’s visionary approach to drug discovery, development and commercialization.  With strong track records in successfully introducing major drugs into the U.S., Chinese and other markets, the D3 Bio team understands the science and market requirements for translational drug development.  Their unique vision for D3 Bio is to create a bridge between insights about the actual clinical needs of patients and the scientific, biomarker-driven research needed to create precision medicines for the world.

George Chen, MD

Co-Founder, Chairman, & CEO

George Chen is an oncologist by training with a successful track record in the world of global pharmaceutical companies.  Prior to founding D3 Bio, Dr. Chen held senior global positions in research, drug development and management at leading institutions, such as the National Institutes of Health, and multinational pharmaceutical companies, such as Eli Lilly, GlaxoSmithKline, Johnson & Johnson and Astra Zeneca.  At these organizations he led development and regulatory registrations of blockbuster drugs into the U.S. and Chinese markets, directing more than 70 IND approvals and more than 30 NDAs.  His medical degree is from the Shanghai Medical College of Fudan University and his MBA is from the Wharton School of Business at the University of Pennsylvania.

John Jin, PHD

Co-Founder, CFO, CBO, & Board Member

John Jin was previously a founding partner at Hanne Capital and former VP of Business Development both at BeiGene and at TaiGen Biotechnology (Taiwan). Dr. Jin had been responsible for venture investment, corporate and business development, government affairs, and global cross-border licensing deals for cancer and other drugs within China and internationally. During his early career, Dr. Jin took on various managerial roles at Clearview Projects, a US boutique strategic advisory firm, Eli Lilly and Millennium Pharmaceuticals. Dr. Jin has more than 20 years of experience in cross-border investment and financing, pharmaceutical business development and drug licensing, and research and development. Dr. Jin has a Bachelor of Medicine from Peking University School of Medicine, an MBA from Wharton School of Business at the University of Pennsylvania and a Ph.D. in Immunology from Cornell University School of Medicine.

R&D pipeline

D3Bio has built a pipeline of multiple pre-clinical stage oncology programs, all of which have first-in-class or best-in-class potential and carry foundational properties targeting immune-pathways or tumor driving mutations. D3 Bio owns global rights to all the programs.

研发管线

德昇济医药已建立一个拥有多个临床前阶段项目的研发管线,针对肿瘤及免疫领域,均具有同类首个或同类最佳的开发潜力。德昇济医药拥有所有项目的全球权益。

In the news

BUSINESS WIRE — Press Release
Nov 17, 2020 07:30 AM EST
D3 Bio Launches with US$200 Million Investment to Develop Precision Medicines Addressing Unmet Patient Needs in Oncology & Immunology
Global biotech headed by seasoned industry veterans secures backing from world-class investor syndicate. Novel approach to guided drug development utilizes clinical and market insights to identify deficiencies in standards of care and match patients with optimal therapies.
Learn More
查看更多
FIERCE BIOTECH — Nick Paul Taylor
Nov 17, 2020 9:00 AM EST
Ex-AstraZeneca executive launches D3 Bio with $200M
Learn More

Contact us

For career opportunities: hr@d3bio.com

For collaboration opportunities: bd@d3bio.com

OFFICE ADDRESSES:
办公室地址:

Room 324, 88 MeiLiang Road; MaShan Street; BinHu District, Wuxi, JiangSu
无锡市滨湖区马山街道梅梁路88号324

1101, 11/F, Building 1, No.6, Lane 38, Yuanshen Road, Pudong, Shanghai
上海市浦东新区源深路38弄6号1号楼1101